What affected survival when lung cancer spread to the brain
Original title: Non-Small Cell Lung Cancer Patients with Brain Metastases and Limited Access to Systemic Therapy.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This was a look back at records of people already treated, not a test of a new treatment.
The short version
People who could get whole-body drug treatment had a lower risk of dying.
What was studied. Doctors looked back at the records of 83 people. All had non small cell lung cancer that had spread to the brain. Most of them could not get drug treatment for the whole body.
What they found. Half of the patients lived less than 2.7 months. About 26.5% were alive at 6 months. About 9.6% were alive at 1 year. People who got whole-body drug treatment had a lower risk of dying. Cancer that had also spread outside the brain raised the risk of dying. whole-brain radiation: Radiation given to the whole brain, rather than aimed at one spot. It is used when there are too many tumors to aim at one at a time. See the glossary did not clearly change how long people lived.
What this means, and what it doesn't
What it could mean: Getting whole-body drug treatment may matter a lot for people in this group. In this study, only 14% were able to get it. If you have brain spread from lung cancer, it is fair to ask your care team what drug options you can get.
What it doesn't mean: This does not mean a new treatment was found, and it is not a cure. The study only looked back at records of care people already had. That kind of study cannot prove what caused the difference in survival. The people who got drug treatment may have been stronger or healthier to begin with. It also does not mean brain radiation is the wrong choice for everyone.
Source: PubMed, October 26, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.